Pataday Twice Daily Relief®

GoodRx

olopatadine 0.1% · ophthalmic solution

Allergy

Approved uses

Allergic conjunctivitis, ocular itching and redness

1 drop in each affected eye BID, 6 to 8 hours apart

Itch and redness relief begins within 27 minutes and lasts at least 8 hours.

OFF-LABELNot in the FDA label for this product

Contact lens induced papillary conjunctivitis

BID for 8 weeks, with lens wear stopped for the first 4 weeks, as dosed in the trial

RCT · n=85 · no placebo arm

Randomized, double-masked three arm trial in 85 soft lens wearers (170 eyes) with mild to moderate papillary conjunctivitis comparing this concentration, fluorometholone 0.1%, and both: reductions in redness, itching and tearing and the gain in lens tolerance were comparable across arms, olopatadine beat fluorometholone for redness at 8 weeks (P=0.01), and IOP rose significantly with fluorometholone (P=0.003). No placebo arm, and the authors ranked the combination first, olopatadine alone second, fluorometholone alone third. The report gives frequency and duration but not the number of drops per dose.

Khurana S, Sharma N, Agarwal T, Chawla B, Velpandian T, Tandon R, Titiyal JS. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. Eye Contact Lens. 2010;36(4):210-214.

Vernal keratoconjunctivitis

BID for 8 weeks, as dosed in the trial

Open-label comparative · n=50

Open-label comparative study, randomized per the authors, in 50 children aged 5 to 15 against bepotastine besilate 1.5% BID: both arms reduced signs and symptoms and were equally effective on itching, bepotastine gave quicker relief of watering, discomfort and hyperemia while olopatadine improved papillary hypertrophy faster, and the authors state the between-drug difference was not statistically significant. No placebo arm, single center, and PubMed indexes it as a journal article rather than a randomized controlled trial. The report gives frequency and duration but not the number of drops per dose.

Sruthi V, Reddy RN, Sowmini K, Grace NS. To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital. Indian J Pharmacol. 2020;52(6):476-481.

Contraindications

Do not use if the solution changes color or becomes cloudy, if you are sensitive to any ingredient in this product, or to treat contact lens related irritation.

Available Forms

Ophthalmic solution, 5 mL bottle, 0.1% (1 mg/mL)

Mechanism of Action

Dual acting topical antiallergic: selective histamine H1 antagonist and conjunctival mast cell stabilizer, so it both blocks histamine already released and limits further mediator release. In a human conjunctival mast cell comparison it inhibited histamine release in a concentration dependent fashion and bound the H1 receptor (Ki 36 nM), while cromolyn and pemirolast produced no significant inhibition.

Warnings & Precautions

External use only: Topical ophthalmic use only, not for ingestion or injection.

Common Side Effects

Ocular and systemic tolerability: No drug-related ocular or non-ocular adverse events in two placebo-controlled challenge studies of 0.05% and 0.1% (169 subjects combined) or in the 98 subject concentration ranging study, all single drop exposures.

Pregnancy & Lactation

Animal studies of toxic doses did not reveal evidence of teratogenicity. No human data is available. It is not known whether this drug is excreted in human milk

Pediatric Use

Labeled for ages 2 and older.